FDA Panel Backs Fall Covid Shots for XFG as Variant Tops 50% of U.S. Cases
Updated
Updated · NBC News · May 28
FDA Panel Backs Fall Covid Shots for XFG as Variant Tops 50% of U.S. Cases
6 articles · Updated · NBC News · May 28
An FDA advisory panel voted Thursday to update fall Covid vaccines to target XFG, a fast-growing Omicron hybrid that now accounts for more than half of new U.S. infections.
CDC data presented to the panel showed XFG.1.1 alone causes about 1 in 4 infections, while officials said the variant carries mutations that may help it partially evade antibodies from prior infection or vaccination.
Moderna and Sanofi told the panel mouse data suggested XFG-targeted shots generated higher antibody levels against circulating strains than the current LP.8.1 formulation, while Pfizer said its XFG shot performed similarly to the current version.
Only 1 committee member abstained, citing limited evidence that an XFG vaccine is clearly better; the recommendation now goes to the FDA, which is expected to authorize manufacturers to start fall production despite leadership vacancies.
Covid activity is still at a medium level nationwide and last season was generally less severe, but hospitalization rates remained highest among babies under 6 months and adults 65 and older.
Is the new COVID vaccine already outdated with the more evasive 'Cicada' variant on the rise?
With protection fading in months, is an annual variant-chasing booster the best long-term strategy?
COVID-19 Vaccine Update 2026-2027: U.S. Targets XFG Variant Amid Policy Shifts and Global Divergence
Overview
The United States is updating its COVID-19 vaccine strategy for the 2026-2027 season by targeting the XFG variant, following a unanimous recommendation from the VRBPAC advisory committee. This decision is based on recent scientific discussions, including comprehensive presentations and thorough reviews of antibody responses to current vaccines and new candidate vaccines with updated spike proteins. The VRBPAC’s recommendation will guide the FDA in aligning vaccine protection with the most prevalent and evolving strains, aiming to maintain strong immunity as the virus continues to change. This proactive approach reflects the ongoing effort to adapt to the shifting landscape of COVID-19 variants.